HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease.

Abstract
Despite a lack of controlled studies confirming its efficacy, recombinant feline interferon-omega (rfeIFN-ω) is used in the treatment of feline upper respiratory tract disease (FURTD), which is usually caused by feline calicivirus (FCV) or feline herpesvirus-1 (FHV-1). The aims of the present study were to investigate whether administration of rfeIFN-ω improves clinical signs in cats with acute FURTD and whether this treatment reduces shedding of FCV. Thirty-seven cats affected with acute FURTD were recruited into a prospective, randomised, placebo-controlled, double-blinded clinical trial. The presence of FCV and/or FHV-1 was determined by performing quantitative polymerase chain reaction (qPCR) on oropharyngeal and conjunctival swabs. Cats were randomly assigned to treatment groups, receiving either placebo or rfeIFN-ω (2.5 MU/kg) subcutaneously, followed by 0.5 MU topically at 8-h intervals via the conjunctiva, intranasally, and orally for 21 days. All cats received additional treatment with antibiotics, expectorants, and inhalation of nebulised physiological saline with camomile. Clinical signs and FCV shedding were evaluated over 42 days. All cats demonstrated improvement in clinical signs during the course of the study, with no significant difference in any of the assessed variables when comparing the two groups. FCV copy numbers decreased more rapidly in cats receiving rfeIFN-ω. Treatment with rfeIFN-ω was not effective in ameliorating clinical signs of acute viral FURTD compared to placebo, but might accelerate a reduction in FCV load in infected cats.
AuthorsAnne C Ballin, Bianka Schulz, Christopher Helps, Carola Sauter-Louis, Ralf S Mueller, Katrin Hartmann
JournalVeterinary journal (London, England : 1997) (Vet J) Vol. 202 Issue 3 Pg. 466-70 (Dec 2014) ISSN: 1532-2971 [Electronic] England
PMID25457261 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Antiviral Agents
  • Interferon Type I
  • Recombinant Proteins
  • interferon omega 1
Topics
  • Administration, Topical
  • Animals
  • Antiviral Agents (administration & dosage, therapeutic use)
  • Calicivirus, Feline (drug effects, isolation & purification)
  • Cat Diseases (drug therapy, virology)
  • Cats
  • Double-Blind Method
  • Female
  • Germany
  • Interferon Type I (administration & dosage, therapeutic use)
  • Male
  • Prospective Studies
  • Real-Time Polymerase Chain Reaction (veterinary)
  • Recombinant Proteins (administration & dosage, therapeutic use)
  • Respiratory Tract Infections (drug therapy, veterinary, virology)
  • Virus Shedding

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: